Functional inducible NOS (iNOS) may be involved in the prolonged lifespan of chronic lymphocytic leukemia cells (B-CLL), although the exact mechanisms implicated remain elusive as yet. In this work, we have examined iNOS expression in normal B lymphocytes and B-CLL cells in pro-and antiapoptotic conditions. Our results demonstrate: (1) The existence of a new splice variant characterized by a complete deletion of exon 14 (iNOS 13-16 14del ), which was preferentially detected in normal B lymphocytes and may represent an isoform that could play a role in the regulation of enzyme activity. (2) The existence of another alternatively spliced iNOS mRNA transcript involving a partial deletion of the flavodoxin region (iNOS 13-16 neg ) was correlated to a decreased B-CLL cell viability. The 9-b-D-arabinofuranosyl-2-fluoradenine or fludarabine (F-ara) treatment induced iNOS 13-16 neg transcript variants, whereas IL-4 enhanced both the transcription of variants, including these exons (iNOS 13-16 pos ), and the expression of a 122 kDa iNOS protein. These results suggest that in B-CLL, a regulation process involving nitric oxide ( K NO) levels could occur by a post-transcriptional mechanism mediated by soluble factors. Our results also provide an insight into a new complementary proapoptotic action of F-ara in B-CLL by the induction of particular iNOS splice variants, leading to the activation of a caspase-3-dependent apoptotic pathway.
Introduction
In chronic lymphocytic leukemia (B-CLL), the most common form of leukemia in the Western world, the clonal accumulation of B tumoral cells appears as a consequence of prolonged survival due to the inhibition of apoptotic cell death rather than increased proliferation. 1 This defective apoptosis in B-CLL cannot be accounted by known genetic aberrations. 2, 3 Since in vitro cultures of purified B-CLL cells undergo spontaneous and rapid apoptosis, 4 multiple humoral and cellular factors controlling apoptosis have been postulated to play a role in the prolonged lifespan of B-CLL cells. [5] [6] [7] Among these signals, several cytokines, such as interferon alpha, 8, 9 interleukin (IL)-4, 10,11 IL-13, 12 IL-6 13 and IL-8, 14 and different drugs have been proposed. Therefore, the size of the B-CLL tumoral population is likely to be regulated directly by extracellular signals that determine whether the cell-death program is engaged.
Recent work postulated that nitric oxide ( K NO), a free radical messenger produced from L-arginine by the action of nitric oxide synthase (NOS), plays an important role in the control of apoptosis in various cell types, [15] [16] [17] [18] including lymphocytes. 19 It has been reported that K NO is a potent biologic mediator implicated in several physiologic and pathophysiologic mechanisms. 20 Recently, Zhao et al 21 and Kolb et al 22 reported that inducible NOS (iNOS) protein can be detected in the cytoplasm of B-CLL cells and proposed that this should provide further insights into the mechanism controlling proliferation and apoptosis in these tumor cells.
The regulation of iNOS expression is complex and occurs at multiple levels, and includes transcriptional and post-transcriptional mechanisms. 23, 24 The human iNOS gene corresponds to a single 37 kb genomic DNA fragment and consists of 26 exons and 25 introns located on chromosome 17 at position 17 cenq11.2 according to Chartrain et al. 25 Recently, Eissa et al 26 have reported four sites of alternative splicing of iNOS mRNA, and suggested that this mechanism may be involved in the regulation of iNOS expression and/or activity. The purine analogue 9-b-D-arabinofuranosyl-2-fluoradenine (fludarabine or F-ara) is being increasingly used in the treatment of lymphoproliferative disorders. 27, 28 It is proposed to be involved in triggering apoptotic cell death through a complex mechanism, including DNA damage (by incorporating a significant amount of F-ara AMP into DNA), Apaf-1 activation, 29 inhibition of ribonucleotide reductase, DNA primase and DNA ligase. 30, 31 However, whereas all these mechanisms have been related to proliferating leukemic cells, B-CLL cells are characterized by the relentless accumulation of tumoral cells with a low ratio of cycling cells blocked at the G1 phase of the cycle. Thus, the precise mechanism by which F-ara kills the indolent B-CLL cells remains unclear. This work aimed to characterize the iNOS expression in B-CLL cells and evaluate in vitro the influence of proapoptotic (F-ara) and survival (IL-4) signal conditions on the (MoAbs) anti-T-cell CD3 (clone UCHT 1), antimonocyte CD14 (clone TUK 4), antinatural killer Cell CD-56 (clone MOC-1), anti-B-cell CD 20 (clone B-Ly1), anti-B-cell CD 19 RPE (clone HD 37) and phycoerythrin-conjugated anti-mouse IgG were purchased from DAKO SA (Paris, France). Tri-Reagent, diaminofluorescein diacetate (DAF 2DA) and 4,5 diaminofluorescein (DAF-2) were obtained from Sigma (St Louis, USA). Rabbit antiiNOS polyclonal antibodies (BD Transduction Laboratories, Lexington, KY, USA) were raised against the carboxy-terminal region of mouse iNOS protein (amino acids 961-1144) and crossreact against human iNOS. HRP conjugated anti-rabbit IgG immunoglobulins, (DAKO) and enhanced chemiluminescence detection Supersignal system (Pierce, Rockford, IL, USA) were used for Western blot detection of iNOS protein. Aminoguanidine (AG), bicarbonate salt , No-nitro-D-arginine methyl ester hydrochloride (D-NAME), and No-nitro-L-arginine methyl ester hydrochloride (L-NAME) were obtained from Sigma (St Louis, USA). Different concentrations of AG from a 200 mM stock solution of pH 7.4 were used as the iNOS inhibitor. IL-4 were obtained from Pharmingen (San Diego, USA). The purine analogue, F-ara was kindly provided by Schering Uruguaya.
PBMC isolation, B-lymphocyte purification and cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation over a Ficoll-Hypaque layer (Lymphoprep, GIBCO-Life Technologies). B-CLL lymphocytes were purified by negative selection using magnetic beads (Dynabeads) coated with MoAbs anti-CD3, CD14 and CD56 according to the manufacturer's instructions. The nonattached cells (95-98% B lymphocytes as assessed by cytometric analysis) were either processed for RNA or protein extraction or resuspended in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal bovine serum (LPS free; Life Technologies, Grand Island, NY, USA), 4 mM glutamine, 1 mM HEPES, 1 mM sodium pyruvate, 200 IU/ml penicillin and 50 mg/ml streptomycin (GIBCO-Life Technologies, Rockville, MD, USA). Cultures were followed up for 48 h in a 5% CO 2 incubator in different conditions: untreated (medium alone), in the presence of either 10 mg/ml of F-ara, 1000 U/ml of IL-4, different doses of AG and 5 mM of L-NAME or D-NAME. B lymphocytes from healthy donors were purified by positive selection by using magnetic beads coated with MoAbs anti-CD19 or CD20, and immediately processed for RNA extraction.
The murine macrophage cell line J774, kindly provided by Noel Alvarez, was used as a known cellular system that produces high fluxes of K NO when activated with 500 IU of IFN-g and 30 mg/ml of LPS.
iNOS mRNA analysis
Total RNA was extracted from 5-10 Â 10 6 purified B lymphocytes by the guanidinium thiocyanate-phenol-chloroform method. 33 cDNA synthesis was performed in a 20 ml reaction volume at 421C for 50 min by using an oligo(dT) 15À18 PCR products were resolved by 2% agarose-gel electrophoresis and stained with ethidium bromide. In an attempt to control the cDNA synthesis, we performed the amplification of the constitutive glyceraldehyde phosphate dehydrogenase (GAPD) mRNA under the same conditions as iNOS amplification in the first round using the following primers: GAPD-F, 5 0 -CTG AGA ACG GGA AGC TTG TC-3 0 ; and GAPD-R, 5 0 -CCT GCT TCA CCA CCT TCT TG-3 0 . Amplified fragments were isolated and purified with GeneClean Kit (Bio 101) and cloned in pGEM s -T (Promega). Electrocompetent XL1-Blue bacteries were transformed by electroporation (BTX Electroporation System 600; Genetronics Biomedical Ltd). Positive colonies were expanded and smallscale plasmid purification was performed using the Wizard s Plus SV Minipreps DNA Purification System (Promega). Purified plasmids were sequenced in an ABI 377 Sequencer with specific primers for pGEM-T s .
iNOS protein detection by Western blot
For Western blot analysis, pellets from cell suspensions were lysed in sample buffer (10 mM Tris-HCl, pH 6.8, 1% SDS and 5% glycerol), followed by boiling for 5 min, sonication and determination of protein concentration by the bicichoninic acid method (Pierce, Rockford, IL, USA). Samples were stored at À701C until use. Total proteins (70 mg) were electrophoresed on an 8% resolution SDS-polyacrylamide gel. Then, the proteins were electrotransferred onto 0.45 mm pore size nitrocellulose membranes, and nonspecific binding sites were blocked overnight in blocking buffer (5% BSA and 0.1% Tween in PBS). For iNOS immunodetection, nitrocellulose filters were probed with the rabbit anti-iNOS polyclonal antibody diluted 1/1000 in blocking buffer for 2 h at room temperature. After three washes with PBS-Tween 0.1%, blots were further incubated for 2 h with HRP conjugated anti-rabbit IgG Ab diluted in PBS-BSA 1 mg/ml. Finally, the filters were developed by using the enhanced chemiluminescence detection system (Supersignal, Pierce).
Cell viability and caspase-3 activity by cytofluorometric analysis
After 48 h of culture in different conditions, B-CLL cell viability and caspase-3 activity were analyzed on a FACScan flow cytometer (Beckton Dikinson). To evaluate cell viability and apoptotic death, 1 Â 10 6 cells were washed in PBS, and stained with propidium iodide and Annexin V-FITC (Annexin V-FITC Apoptosis Detection Kit (Sigma, St Louis, USA)) according to the manufacturer's instructions. A viability index was expressed as the percentage of viable cells over the total cell count (live and dead cells). A PhiPhiLux G 1 D 2 kit (OncoImmunin, Inc., Gaithersburg, MD, USA) was used to evaluate caspase-3 activity following the manufacturer's instructions. Briefly, the purified B cells were incubated at 371C for 60 min with 10 mM DEVD G 1 D 2 substrate solution. Cells were then washed once with ice-cold cytometry dilution buffer and resuspended in 500 ml of fresh dilution buffer. Samples were analyzed on the FACSscan flow cytometer using the FL1 channel. An activity index was expressed as percentages of cells with respect to caspase-3 activity of total cells (live and dead cells).
K NO production in living cells
In order to evaluate K NO production by B lymphocytes, the membrane-permeable diaminofluorescein diacetate (DAF-DA) was used. DAF-DA is quickly transformed in DAF-2 by esterases in the cytosol, and this probe can react with N 2 O 3 (produced by K NO and oxygen reaction) to form the highly fluorescent triazolofluorescein (DAF-2T), which could be detected by fluorescence microscopy and by fluorimeter equipment.
Fluorescence microscopy: One to five million cells were incubated with 1 mM DAF-DA for 90 min at 371C in culture medium without serum. After centrifugation, the pellet was suspended in 100 ml of medium with mouse MoAb anti-human CD14 monocyte marker (DAKO), and incubated at 41C for 30 min. After washing with PBS, phycoerythrin-conjugated antimouse IgG was added to cells and incubated for 30 min at 41C. The cells were finally washed and suspended in 50 ml of cold RPMI. In order to control the specificity of DAF-DA NO detection, PBMC obtained from B-CLL patients were cultured for 48 h in the presence of 5 mM of both NOS inhibitors: AG and L-NAME and 5 mM of D-NAME (inactive isomer of L-NAME). The cells were collected and incubated with 1 mM DAF-DA and anti-CD19-RPE MoAb for 60 min at 41C in culture medium without serum. Images were obtained with a fluorescence microscopy (NIKON Fluorescence Microscopy Optiphot) and Digital Camera (KodaK DC290 Zoom).
Fluorimetric analysis: Purified B-CLL were suspended in Krebs Ringer phosphate buffer supplemented with 5 mM arginine (KRP-Arg): 120 mM NaCl, 4.8 mM KCl, 0.54 mM CaCl 2 , 1.2 mM MgSO 4 , 11 mM glucose and 15.9 mM sodium phosphate, pH 7.2. A total of 50 000 cells were plated in a 96-well culture plate, then 1 mM DAF-DA was added in a 200 ml final volume and finally, the DAF-2T fluorescence was measured in a kinetic mode on a plate fluorimeter (Fluostart Galaxy BMG Lab Technologies, Germany) setting the following conditions: excitation and emission at the top of the plate with wavelength at 485 and 520 nm, respectively, gain at 20, temperature controlled at 371C and shaking before each measure. The pH of final DAF-DA solution was controlled and it was 7.4. When B lymphocytes were tested, a long-time assay was required (5 h) and cell viability was controlled at the final time assay by exclusion of trypan blue colorant (100% with respect to initial cell viability). As a positive control, we assayed the murine macrophage J774 cell line, which was cultured to confluence in a 96-well culture plate, and then it was activated in culture medium for 6 h at 371C with LPS 30 mg/ml and IFN-g 500 U/ml. The supernatant was removed and KRP-Arg containing 1 mM DAF-DA was added in order to measure DAF-2T generation in the same conditions described above. Only 1 h of time assay was required to obtain quantifiable values.
The mean values for the first and last five measures at each well were calculated, and their differences were obtained. These values were interpolated into a calibration curve obtained previously with 1 mM DAF-2 and different doses of authentic K NO diluted in PBS 100 mM to maintain the pH at 7.4. Then fluxes of K NO were calculated taking into account the time of the assay.
Statistical analysis
For statistical analysis, the nonparametric Mann-Whitney rank test was used and P-value calculation was obtained.
Results

B lymphocytes from healthy and leukemic patients express different iNOS mRNA transcripts
In order to detect iNOS mRNA, we have developed two PCR assays. One of them was reported previously 21 and amplified a region included in exon 26 at the 3 0 end of the iNOS mRNA (iNOS 26). As shown in Table 1 for purified B cells in basal conditions, 18 out of 20 (90%) patients displayed the expected 259 bp fragment, whereas only three out of seven (43%) healthy donors were positive (data not shown).
In our laboratory, we previously developed a nested PCR strategy to amplify low levels of iNOS mRNA expression in lymphocyte cells. The first round of amplification spanning the region from exons 12 to 19 and the second round amplified an expected fragment of 317 bp from exons 13 to 16, as depicted in Figure 1(a) . As shown in Table 1 and for representative cases in Figure 1 (b), 16 out of 20 (80%) patients in basal conditions displayed a highly represented 317 bp fragment (iNOS 13-16 pos ), whereas 12 out of 20 (60%) patients displayed an additional 212 bp fragment. In only two cases (patients 9 and 13, Table 1 ), the fragment corresponding to exon 26 was not amplified and this result can be explained by the difference in the sensitivity of the two techniques (nested vs classical RT-PCR). In four out of 20 (20%) patients, no expression of 317 or 212 bp fragments was observed (iNOS 13-16 neg ), whereas the fragment corresponding to exon 26 was present in all these cases, indicating the presence of iNOS mRNA, and suggesting a deletion in this middle region.
In contrast, in B lymphocytes from healthy donors, high levels of the 212 bp fragment were detected in five out of seven (71%) samples, whereas two out of seven (29%) expressed low levels of the iNOS 13-16 pos . Nucleotide sequence demonstrated that all fragments were 100% homologous to reference iNOS sequence, 25 but as shown in Figure 2 , the 212 bp fragment displays a 105 bp deletion corresponding to complete exon 14 (iNOS 13-16 14del ). These results show that a yet unreported alternative splice form involving a deletion of exon 14 is highly represented in normal B lymphocytes.
Proapoptotic culture conditions modulate the expression of iNOS mRNA variants in B-CLL B-CLL cells undergo spontaneous apoptosis following exposure to culture conditions 4 and this process is enhanced by F-ara in vitro treatment. 29 We have evaluated these two proapoptotic culture conditions by analyzing cell viability and iNOS mRNA expression.
As shown in Table 1 , the iNOS fragment corresponding to exon 26 was constantly present in the 20 studied patients after 48 h of F-ara treatment. However, in the same culture conditions, the iNOS 13-16 pos could only be detected in 10 out of 20 (50%) of these cell samples. The other 50% (10 out of 20) were iNOS 13-16 neg . Similar results were obtained in the untreated group: 19 out of 20 (95%) patients displayed the fragment corresponding to exon 26, and 13 out of 20 (65%) cell samples expressed the fragment iNOS 13-16 pos , whereas seven out of 20 (35%) were iNOS 13-16 neg . These results suggest that whereas all the cases displayed iNOS transcripts corresponding to the 3 0 end of mRNA in proapoptotic conditions, the central region of iNOS mRNA could be amplified in only half of them. iNOS post-transcriptional regulation in B-CLL AC Tiscornia et al Figure 3 displays the kinetics of two representative patients studied for iNOS mRNA expression of B cells untreated and treated with F-ara at 0, 24 and 48 h of culture. In Figure 3(a) , the suppression of iNOS 13-16 pos after 48 h of treatment with F-ara was representative for seven patients, whereas in Figure 3(b) , the F-ara treatment did not affect the iNOS 13-16 pos expression representing 10 patients.
According to the absence or the presence of iNOS 13-16 PCR products after 48 h of culture in proapoptotic conditions, samples were segregated into two groups. As depicted in Figure 3(c) , the mean index of viability associated to the untreated condition was 55716.2% for the iNOS 13-16 pos group, and 27.6715.5% for the iNOS 13-16 neg group (P ¼ 0.0063). In F-ara-treated B-CLL cells, it was 40.3713.1% for the iNOS 13-16 pos group and 15.978.6% for iNOS 13-16 neg (P-value ¼ 0.0011). These results suggest that the expression of the iNOS variant displaying complete 13-16 exons is associated to higher cell survival.
IL-4 treatment protects against in vitro apoptotic death and modulates the expression of iNOS variants
To analyze the iNOS variant expression in different culture conditions, five patients were evaluated. Purified B cells were cultured for 48 h: (a) untreated (medium alone), (b) with 10 mg/ ml F-ara, (c) with 1000 U/ml IL-4 and (d) with 1000 U/ml IL-4 and 10 mg/ml of F-ara. All five cases were evaluated for cell Figure 2 Sequence comparison of iNOS PCR fragments amplified from exons 13 to 16: sequence alignment of the 317 and 212 bp amplified fragments was compared to a reference iNOS mRNA from Gene Bank (GI 687680). A deletion of 105 bp in the 212 bp fragment involves the complete exon 14. viability, caspase-3 activity, detection of exons 13-16 and 26 from iNOS mRNA and iNOS protein expression. As shown in Figure 4 (a), the mean index of viability after 48 h culture in the presence of IL-4 was 8772.4%, whereas for untreated cells it was 60719.1%. The mean indexes of viability of F-ara-and IL-4 þ F-ara-treated cells were 41719.0 and 64.872.4%, respectively.
In all five cases, exon 26 expression from iNOS mRNA could always be detected whatever the culture condition. As for exons 13-16 expression in either the IL-4 or IL-4 þ F-ara groups, only the 317 bp fragment was detected in four out of five cases (data not shown).
Protein expression was detected with a specific polyclonal antibody directed against the carboxy-terminal region of iNOS protein (amino acids 961-1144) corresponding to exons 21-25. Four different immunoreactive bands were detected. Although the theoretical mass of human iNOS protein is 131 kDa, the high molecular weight protein detected in purified B-CLL lysates was 122 kDa and displayed a slightly lower molecular weight than that detected in the 130 kDa positive control obtained from a lysate of murine macrophage J774 cell line stimulated with IFNg and LPS. The other three bands corresponded to molecular weights of 69, 60 and 21 kDa. As depicted in Figure 4 (b) for a representative case, both the IL-4 treatment and IL-4 þ F-ara treatment resulted in high iNOS protein expression.
These results indicate that the survival signal resulting from IL-4 treatment is associated with the detection of exons 13-16 by PCR and/or high levels of iNOS protein. To confirm that cell death in the five purified B-CLL cells was the consequence of apoptotic machinery activation, we assayed caspase-3 activity by cytometric analysis in all culture conditions. As shown in Figure 4 (c), the mean values of active caspase-3-positive cells for five patients were 25 and 37.8% for untreated and F-aratreated cells, respectively. IL-4 treatment resulted in a significantly lower percentage of cells with caspase-3 activity (5.6%), whereas the association of IL-4 þ F-ara treatment increased this percentage to 23.2%. These results confirmed that F-arainduced cell death was through the induction of apoptosis and that IL-4 treatment was able to downregulate proapoptotic signals in these culture conditions, but was unable to avoid F-ara apoptotic cell death activation completely (IL-4 þ F-ara culture condition). Given that this latter condition results in the overexpression of the splice variant including exons 13-16 ( Figure 4(b) ), these results suggest that IL-4 induces the expression of this variant, succeeds to rescue a number of cells from F-ara-induced cell death, but is not sufficient to prevent apoptosis by F-ara completely.
Low levels of
K NO produced by B-CLL could modulate apoptotic pathway
To evaluate K NO production in living PBMC cells, membranepermeable DAF-DA was used as a probe for K NO detection simultaneously to monocytes cells identification as known K NO-producing cells. Whereas in B-CLL cells we detected highly green fluorescence from DAF-2T in lymphocyte cells, in PBMC from healthy donors positive CD-14 cells were mainly stained as depicted in Figure 5(a) . These results suggested that B lymphocytes from B-CLL patients could produce increased levels of K NO compared to normal B cells. As shown in Figure 5(b) , the green fluorescence obtained on B lymphocytes from CLL patients was inhibited in an important fraction of B cells with the NOS inhibitors AG and L-NAME, whereas no inhibition was detected by using the D-NAME isomer. Cell viability, caspase-3 activity, iNOS mRNA and iNOS protein detection after in vitro treatment of B-CLL with IL-4. (a) B-CLL cell viability at 48 h in different culture conditions. Purified B-cells from five B-CLL patients were cultured for 48 h in different conditions -untreated (untreat.), with 10 mg/ml F-ara (F-ara), 1000 U/ml IL-4 (IL-4), 10 mg/ml F-ara and 1000 U/ml IL-4 (IL-4 þ F-ara) -and cell viability was evaluated by cytometric analysis. Bars represent a viability index means7s.d. (percentage of viable cells over total cells count). (b) A representative case from the five above analyzed B-CLL patients: results for cell viability (up), PCR iNOS 13-16, iNOS 26 and GAPD (middle), and Western blot (down) were aligned. Letters are used to name samples: A -activated murine macrophage sample (positive control for Western blot), B -molecular marker of Western blot, Csamples from purified B cells from a B-CLL patient in basal conditions (T ¼ 0). The following letters correspond to samples from 48 h culture conditions: D -untreated, E -treated with 10 mg/ml F-ara, F -treated with 1000 U/ml IL-4 and G -treated with 10 mg/ml F-ara and 1000 U/ ml IL-4. (c) B-CLL caspase-3 activity at 48 h of different culture conditions. Purified B cells from five B-CLL patients were cultured for 48 h without drug treatment (untreated.), with 10 mg/ml F-ara (F-ara), 1000 U/ml IL-4 (IL-4), 10 mg/ml F-ara and 1000 U/ml IL-4 (IL-4 þ Fara), and caspase-3 activity was evaluated quantifying the fluorogenic cleaved product by flow cytometry. Bars represent activity index means7s.d. (expressed as percentage of cells with caspase-3 activity with respect to total cells). 
Experiments evaluating
K NO fluxes produced by living B-CLL cells and activated murine macrophage J774 cells were performed.
K NO production in living B-CLL cells has been reported previously (1.5 pmol K NO/h/10 6 cells). 21 In agreement, as shown in Figure 5(c) , B-CLL cells showed a mean value of 4 pmol K NO/h/10 6 cells, which contrasts with the 392 pmol/ h/10 6 cells K NO production of IFN-g-LPS-activated murine macrophage. These very low levels from B-CLL cells are at the limit of the assay sensitivity and constitute a methodological limiting step in order to correlate the K NO produced by the presence of the above different iNOS splice variants with cell viability.
We selected an indirect method to evaluate iNOS activity in the modulation of B-cell survival by using AG (a specific iNOS inhibitor). Cell viability and caspase-3 activity were measured after 48 h of cell culture with different AG concentrations. Figure 5(d) shows that the percentage of cells with caspase-3 activity directly correlates to increasing AG concentrations, whereas the converse holds true for cell viability, suggesting that iNOS activity could modulate apoptotic cell death in B-CLL.
Overall, our results in B-CLL cells showed that an increased F-ara apoptotic effect was associated with the expression of iNOS variant without exons 13-16 (iNOS 13-16 neg ) and low levels of iNOS protein. In contrast, IL-4 treatment resulted in the overexpression of iNOS variant containing exons 13-16 (iNOS 13-16 pos ), and an important increase of iNOS protein expression.
Discussion
K NO produced by a constitutively expressed iNOS has been proposed to be implicated in the prolonged lifespan of B lymphocytes in B-CLL patients. 21 Upregulation of iNOS expression either by CD-23 21 ligation or by IL-4 treatment 34 is associated with the protection of cultured B-CLL cells from apoptotic death. The mechanisms proposed for K NO antiapoptotic action in lymphocytes (reviewed in Kolb 35 ) are related to: (a) a dependent or independent cGMP pathway, (b) caspase-3 inhibition by S-nitrosylation of the Cys-163 in the catalytic site, (c) prevention by K NO of caspase-8-mediated cleavage of the antiapoptotic protein bcl-2, as a way to avoid cytochrome c release and caspase-3 activation and (d) the mitochondrial hyperpolarization by inhibition of cytochrome c oxidase. 36 The regulation of iNOS expression is complex and occurs at multiple sites, including transcriptional and post-transcriptional mechanisms. 23, 24 In this work, we have analyzed two regions of iNOS mRNA: the 3 0 end (exon 26) and a conserved central region (exons [13] [14] [15] [16] .
In agreement with Zhao et al 21 and Levesque et al, 34 B lymphocytes from 90% of B-CLL patients constitutively expressed iNOS transcripts as assessed by RT-PCR of exon 26 in contrast to a 43% positivity observed for healthy donors. Different from normal B cells, these results suggest that there is an in vivo basal transcription for the iNOS gene, in the case of B-CLL cells. The role of this phenomenon in CLL pathogenesis and the regulation pathways involved in it remain to be elucidated.
With respect to exons 13-16 expression, the expected 317 bp and an additional 212 bp fragments were amplified in B-CLL. Interestingly, in normal B cells, this latter fragment, resulting from a complete exon 14 deletion, was highly expressed. In a previous work, Eissa et al 26 reported four different splice variants for iNOS: (a) deletion of exon 5 that results in a truncated protein, (b) deletion of exons 8-9, (c) deletion of exons 9-11 and (d) deletion of exons 15-16. Thus, here we report a new splice variant characterized by complete exon 14 deletion. This deletion involves the flavodoxin region, and could modify the FMN domain, which plays a role in electron transfer from the NADPH to the Hem domain. We can speculate that this iNOS variant could be a post-transcriptional mechanism implicated in the downregulation of K NO levels. Ongoing work in our lab is directed to compare enzymatic activity and K NO production by recombinant full-length iNOS protein and iNOS protein with a deleted exon 14.
Interestingly, in some B-CLL patients, we could detect the presence of exon 26 (iNOS 26), but neither the 317 bp nor the 212 bp fragment (NOS 13-16 neg ), which could suggest the existence of iNOS splice variant, including deletion of exons 15-16 26 that causes an in-frame deletion also involving the flavodoxin region. 26 Zhao et al 21 reported the spontaneous expression of iNOS mRNA by two pairs of primers, one of them amplifying exon 26 and the other exons 8-11, whereas Levesque et al 34 found similar results for primers amplifying exons 9-10. These results indicate that in B-CLL cells, splicing variants involving either exons 8-9 or 9-11 have never been detected. Interestingly, exon 8 plays a major role in the dimerization process implicated in full enzymatic activity. 37, 38 When purified B-CLL cells were cultured in proapoptotic conditions (untreated and F-ara treatment), exon 26 could be detected in almost all cases, whereas exons 13-16 could be amplified in only half of them. In both conditions, cell viability was significantly higher in the group expressing exons 13-16 when compared to nonexpressing cases. As for PBMC and purified B cells treated with F-ara for 48 h, cell viability appeared better sustained in PBMC, which was associated to the presence of low levels of iNOS 13-16 pos (data not shown). These results suggest the presence of an iNOS expression posttranscriptional control, mediated by other mononuclear cell delivered signals, which could prevent cell death by inducing iNOS mRNA variants containing exons 13-16.
IL-4 can prevent spontaneous apoptosis of cultured B-CLL cells and IL-4 and IFN-g can induce iNOS expression in these cells. 5, 34 iNOS expression is typically regulated in a synergistic manner by a combination of inducers of the NF-kB pathway and by interferon-Jak-STAT pathways, except in the instance where single agents are effective for iNOS induction. 24 The iNOS promoter contains several interferon-g activation sites (GAS elements) regulated by STAT-1 and STAT-6. 39 Recent reports have demonstrated that in B-CLL, STAT-1 is activated 40 and STAT-6 nuclear translocation is induced by IL-4 41 and controls iNOS expression at the transcription level. Our results show that IL-4 treatment is correlated to the inhibition of apoptotic cell death, the amplification of iNOS variants containing exons 13-16 and increased iNOS protein expression.
These results suggest the existence of a possible fine control of K NO levels through post-transcriptional regulation mechanisms mediated by soluble factors like IL-4. This cytokine induces iNOS splice variants associated with cell survival. This is in agreement with a recent report using oligonucleotide microarrays, demonstrating a five-fold increased expression of the IL-4 receptor in CLL B-cells when compared to normal tonsilar CD5 þ B cells. 42 On the other hand, a potent increase of IL-4 levels in T cells from CLL patients was also reported. 43, 44 Thus, iNOS mRNA variants induced by IL-4 signaling pathway could play a role in the survival advantage displayed by leukemic B-CLL cells.
As predicted, exon deletions implicated in the flavodoxin region might produce either a suppression or a decrease of K NO production by these alternative splicing variants. The methodological limiting step to quantify low levels of K NO was the reason why we could not confirm this idea. Methodological progress in quantification procedures may allow one in the future to better analyze these subtle differences and to better define the role of the different iNOS splice variants. Also, the results obtained with different AG concentrations showed that the inhibition of K NO production was also correlated to apoptotic death.
Four different molecular weight-specific iNOS bands were detected by Western blot with an antibody directed against the carboxy terminus of the iNOS protein. In all cases, the higher band, with a molecular weight of 122 kDa, was slightly smaller than murine macrophage iNOS (131 kDa). The theoretical molecular mass for human iNOS protein is 131 kDa, and the 9 kDa mass difference could be explained either by alternative splicing or differences in glycosylation. Recent work 45, 46 suggested that a novel mechanism involving iNOS ubiquitination and proteasomic proteolysis could also play a role in the regulation of iNOS activity. As previously proposed by Zhao et al 21 and Coers et al, 47 the small molecular weight bands revealed by Western blot could be considered as proteolytic degradation products. However, further work in this direction should be performed in order to confirm this hypothesis.
In conclusion, we report a new iNOS splice variant characterized by complete deletion of exon 14, which is highly represented in normal B lymphocytes and might be related to the downregulation of K NO production. Our results also favor the existence of post-transcriptional mechanisms involved in iNOS regulation, which may be important in the modulation of cell life or cell viability in B-CLL. They also suggest a new complementary proapoptotic action of F-ara in B-CLL by the induction of a particular iNOS splice variant, leading to the activation of caspase-3-dependent apoptotic pathway.
